📣

GLENMARK

on Fire! 🔥

🏆 Stock Surge Alert:

shares have soared nearly 33% in the past month, hitting a fresh 52-week high after announcing a game-changing licensing deal. 💰 Massive Deal with AbbVie: Its subsidiary Ichnos Sciences signed a landmark $2 billion licensing agreement, including a $700 million upfront payment for cancer therapy ISB‑2001—one of India’s biggest pharma deals ever! 📈 Analyst Confidence Up: Brokerages have reaffirmed a “Buy” rating, citing improved margin outlook and raised target price from ₹1,670 to ₹2,545. 🤝 Mutual Funds on Buying Spree: Strong institutional demand helped drive the stock to an intraday high of ₹2,286 recently. 📌 Why It Matters This deal gives Glenmark’s US arm the capital freedom to drive innovation while reducing pressure on the parent company’s balance sheet. With new launches, rising margins, and bullish outlook, Glenmark 3.0 is turning heads in pharma circles. 🚀 transformation story is just getting started!